Abstract
Azacitidine (Vidaza; Pharmion), an inhibitor of DNA methylation, was approved by the US FDA for the treatment of myelodysplastic syndromes in May 2004. It is the first drug to be approved by the FDA for treating this rare family of bone-marrow disorders, and has been given orphan-drug status. It is also a pioneering example of an agent that targets 'epigenetic' gene silencing, a mechanism that is exploited by cancer cells to inhibit the expression of genes that counteract the malignant phenotype.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Different methylation signatures at diagnosis in patients with high-risk myelodysplastic syndromes and secondary acute myeloid leukemia predict azacitidine response and longer survival
Clinical Epigenetics Open Access 14 January 2021
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
List, A. F., Vardiman, J., Issa, J. -P. & DeWitte, T. M. Myelodysplastic syndromes. Hematology (Am. Soc. Hematol. Educ. Program) 297–317 (2004).
Hofmann, W. -K. et al. Myelodysplastic syndromes. Hematol. J. 5, 1–8 (2004).
Herman, J. G. & Baylin, S. B. Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med. 349, 2042–2054 (2003).
Egger, G., Liang, G., Aparicio, A. & Jones, P. A. Epigenetics in human disease and prospects for epigenetic therapy. Nature 429, 457–463 (2004).
FDA labelling information [online], <http://www.fda.gov/cder/foi/label/2004/050794lbl.pdf> (2004).
Greenberg, P. et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89, 2079–2088 (1997).
Silverman, L. R. et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J. Clin. Oncol. 20, 2429–2440 (2002).
Faderl, S. & Kantarjian, H. M. Novel therapies for myelodysplastic syndromes. Cancer 101, 226–241 (2004).
Anzai, H., Frost, P., & Abbruzzese, J. L. Synergistic cytotoxicity with 2′-deoxy-5-azacytidine and topotecan in vitro and in vivo. Cancer Res. 52, 2180–2185 (1992).
Kantarjian, H. et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood 102, 2379–2386 (2003).
List, A. et al. Efficacy of lenalidomide in myelodysplastic syndromes. N. Engl. J. Med. 352, 549–557 (2005).
Bird, A. DNA methylation patterns and epigenetic memory. Genes Dev. 16, 6–21 (2002).
Kuendgen, A. et al. Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. Blood 104, 1266–1269 (2004).
Wijermans, P. et al. Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J. Clin. Oncol. 18, 956–962 (2000).
Claus, R. & Lubbert, M. Epigenetic targets in hematopoietic malignancies. Oncogene 22, 6489–6496 (2003).
Saiki, J. H. et al. 5-azacytidine in acute leukemia. Cancer 42, 2111–2114 (1978).
Issa, J. P. et al. Phase I study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (Decitabine) in hematopoietic malignancies. Blood 103, 1635–1640 (2004).
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Issa, JP., Kantarjian, H. & Kirkpatrick, P. Azacitidine. Nat Rev Drug Discov 4, 275–276 (2005). https://doi.org/10.1038/nrd1698
Issue Date:
DOI: https://doi.org/10.1038/nrd1698
